No Data
No Data
Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Leerink Upgrades AN2 Therapeutics to Outperform Rating With $5 Price Target
07:12 AM EDT, 07/05/2024 (MT Newswires) -- Leerink Upgrades AN2 Therapeutics to Outperform Rating With $5 Price Target Price: 2.6500, Change: -0.06, Percent Change: -2.21
Leerink Partners Upgrades AN2 Therapeutics to Outperform
Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform.
Express News | Octagon Capital Advisors LP Reports 10.1% Passive Stake in AN2 Therapeutics as of June 13 - SEC Filing
Leerink Partners Upgrades AN2 Therapeutics(ANTX.US) to Buy Rating, Maintains Target Price $5
Leerink Partners analyst Joseph Schwartz upgrades $AN2 Therapeutics(ANTX.US)$ to a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 41.5%
Optimistic Outlook for AN2 Therapeutics' Epetraborole Despite Initial Concerns
No Data
NVDAvsTSLA : No one knows the results only the company themselves
TrytosaveabitOP NVDAvsTSLA: That’s why I said ( upcoming ) meaning later when they release the results/data! If it’s good it could be a catalyst. Hehehe
NVDAvsTSLA TrytosaveabitOP: Agree. Back to $20 is easy once the tests are good
TrytosaveabitOP NVDAvsTSLA: That would be a great thing to see! GL to ya![undefined undefined](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)